We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

22 hedge funds and large institutions have $8.24M invested in DiaMedica Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

111% more capital invested

Capital invested by funds: $3.91M → $8.24M (+$4.33M)

47% more funds holding

Funds holding: 15 → 22 (+7)

14% more ownership

Funds ownership: 6.72% → 20.72% (+14%)

Holders
22
Holders Change
+7
Holders Change %
+46.67%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$3.41M
2
NCM
Nantahala Capital Management
Connecticut
+$3.1M
3
GPCM
Granite Point Capital Management
Massachusetts
+$1.03M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$665K
5
MHP
Manatuck Hill Partners
Connecticut
+$325K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$91.3K
2
WVP
Worth Venture Partners
New Jersey
-$67.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$2.31M +$3.41M +825,297 New
NCM
2
Nantahala Capital Management
Connecticut
$2.14M +$3.1M +750,000 New
GPCM
3
Granite Point Capital Management
Massachusetts
$1.34M +$1.03M +250,000 +110%
MHP
4
Manatuck Hill Partners
Connecticut
$983K +$325K +78,700 +29%
Vanguard Group
5
Vanguard Group
Pennsylvania
$677K +$665K +160,885 +198%
WVP
6
Worth Venture Partners
New Jersey
$296K -$67.4K -16,314 -13%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$161K +$165K +39,967 +228%
BlackRock
8
BlackRock
New York
$108K +$26.1K +6,320 +20%
Renaissance Technologies
9
Renaissance Technologies
New York
$72K +$107K +25,849 New
Northern Trust
10
Northern Trust
Illinois
$35K +$51.5K +12,465 New
Millennium Management
11
Millennium Management
New York
$30K -$91.3K -22,091 -67%
William Blair & Company
12
William Blair & Company
Illinois
$28K – – –
UBS Group
13
UBS Group
Switzerland
$24K +$35.1K +8,500 New
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$16.2K – – –
PFGIA
15
Patriot Financial Group Insurance Agency
Massachusetts
$8K – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$7K +$1.87K +452 +19%
APA
17
American Portfolios Advisors
New York
$7K +$10.3K +2,500 New
Deutsche Bank
18
Deutsche Bank
Germany
$2K +$2.21K +534 +3,141%
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$1K – – –
Wells Fargo
20
Wells Fargo
California
– +$277 +67 New

DMAC Hedge Fund Activity: Q1 2020 in Review

22 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2020, worth a combined $8.24M — up 111% from $3.91M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new DMAC positions and 0 closed out — a net gain of 7 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.41M. The largest seller was Millennium Management, cutting an estimated $91.3K.

  • 22 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2020, up from 15 in Q4 2019.
  • Funds reported $8.24M of DiaMedica Therapeutics stock for Q1 2020, up 111% quarter-over-quarter.
  • 7 funds opened new DiaMedica Therapeutics positions in Q1 2020 and 0 closed out, a net change of +7 holders.
  • The largest DiaMedica Therapeutics buyer in Q1 2020 was Stonepine Capital Management, an estimated $3.41M added.
  • The largest DiaMedica Therapeutics seller in Q1 2020 was Millennium Management, an estimated $91.3K sold.

Based on aggregated 13F filings for Q1 2020.